CytoDyn Inc. Form 8-K (July 9, 2021)

Summary

A Form 8-K current report of CytoDyn Inc. dated July 9, 2021 and signed by Antonio Migliarese, Chief Financial Officer. Item 2.03 reports that on July 2, 2021 an arbitration panel issued its decision, after a five-day arbitration hearing in March 2021, on a claim by ProstaGene, LLC against the company and counterclaims by the company relating to approximately 3.1 million shares of common stock in escrow for indemnification claims. The report states that the panel determined ProstaGene is entitled to release of the shares and a cash monetary award of approximately $6.2 million, plus interest, fees and costs estimated at approximately $1.4 million. The company expects to satisfy the award obligations within 30 days.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act

Date of Report (Date of earliest event reported): July 9, 2021 ( July 2, 2021 )

CytoDyn Inc.

(Exact name of registrant as specified in its charter)

Delaware | 000-49908 | 83-1887078
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.)

1111 Main Street , Suite 660

Vancouver , Washington 98660

(Address of principal executive offices, including zip code)

(360) 980-8524

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
None | None | None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.03. | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On July 2, 2021, an arbitration panel issued its decision following a five-day arbitration hearing held in March 2021 concerning a previously disclosed claim by ProstaGene, LLC (“ProstaGene”), against CytoDyn Inc. (the “Company”), as well as counterclaims by the Company, relating to approximately 3.1 million shares of the Company’s common stock (the “Shares”) held in escrow for certain indemnification claims asserted by the Company in connection with the acquisition of certain intangible assets from ProstaGene in November 2018. ProstaGene also sought monetary damages related to the delay in the release of the Shares. The Company, as of February 28, 2021, as disclosed in its Quarterly Report on Form 10-Q for the Company’s 2021 third fiscal quarter, recognized a full impairment charge against the net carrying value of certain of the acquired intangible assets. Nonetheless, the arbitration panel determined that ProstaGene is entitled to release of the Shares, as well as a cash monetary award in the amount of approximately $6.2 million, plus interest, fees and costs estimated to total approximately $1.4 million. The Company expects to satisfy the arbitration award obligations within 30 days following the date of the award.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYTODYN INC.
Date: July 9, 2021 | By: | /s/ Antonio Migliarese
Antonio Migliarese
Chief Financial Officer

File and source

File

SEC_CYDY_8-K_filed2021-07-09_0001193125-21-211981.htm

Size

22,612 bytes

SHA-256

a9ccc0d6ccb7dd879e660d7bd5428c8458665843836be56f2b747fda2ce0025a

Our copy

SEC_CYDY_8-K_filed2021-07-09_0001193125-21-211981.htm

Original

www.sec.gov